INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™
Key Highlights
- ➤INmune Bio (INMB) and Quantum Computing (QUBT) launch quantum-AI drug research collaboration
- ➤Stage 1 engagement makes QCi’s first commercial pharmaceutical and biotechnology customer
- ➤Dirac-3S will analyze clinical datasets for XPro indications and response biomarkers
- ➤Companies will compare quantum optimization against conventional statistical and machine-learning methods
Expert Statements
David Moss, Chief Executive Officer of INmune Bio
“We've built a large clinical dataset on Alzheimer’s and other diseases, backed by years of work with XPro”
David Moss, Chief Executive Officer of INmune Bio
“This collaboration allows us to examine patient populations and biomarkers most likely to predict responses by analyzing large data sets.”
David Moss, Chief Executive Officer of INmune Bio
“We'll look for the diseases with the greatest potential for success, those whose human biology matches what we've already seen XPro do, starting with rare diseases where trials can be smaller, faster and more capital-efficient, and where qualifying pediatric approvals may earn a Priority Review Voucher.”
Yuping Huang, Chairman and Chief Executive Officer of Quantum Computing Inc.
“This is a great example of what practical quantum computing can look like today”
Yuping Huang, Chairman and Chief Executive Officer of Quantum Computing Inc.
“INmune Bio has a complex scientific problem and a substantial body of clinical and biological data.”
Yuping Huang, Chairman and Chief Executive Officer of Quantum Computing Inc.
“Our job is to bring new computing capabilities to that problem and see what we can learn.”
Yuping Huang, Chairman and Chief Executive Officer of Quantum Computing Inc.
“The potential to help researchers make better decisions about future treatments is exciting, and it opens an important new market for QCi.”
* Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro * Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development BOCA RATON, Fla. and HOBOKEN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's disease and other disease conditions.
The collaboration brings together INmune Bio's data from pre-clinical research through four clinical trials and understanding of disease biology with QCi's Dirac-3S quantum optimization machine. Working with clinical and publicly available biomedical datasets, the companies intend to use quantum computing alongside AI and conventional data analytics to uncover relationships that could help find diseases driven by the same biology XPro targets, and to prioritize those with the greatest potential for success.
Get started
Create a free account to read the full story.